← Human Trials & Peer-Reviewed Studies
Effect of long-acting growth hormone treatment on endogenous growth hormone secretion in prepubertal patients with idiopathic short stature: A preliminary study.
Plain-language guide to PMID 35868146 (2022): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 4 patients.
Key Facts
- PMID
- 35868146
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Choi HS et al. (6 authors)
- DOI
- 10.1016/j.ghir.2022.101486
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Long-acting growth hormone (LAGH) is emerging to be a new preparation for treatment of short stature.
Participants included 10 GH-naïve prepubertal children with idiopathic short stature (ISS).
Who Took Part
The abstract describes 4 patients taking part.
PubMed indexes the participants as children.
Nocturnal endogenous GH secretory profiles obtained from 12-h blood samplings at 30-min interval were assessed at baseline and 2 weeks after the completion of GH treatment.
Post-treatment changes in height velocity, height standard deviation score (SDS), metabolic parameters, and adverse events were measured.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
Topics PubMed links to this paper include Blood Specimen Collection, Body Height, Dwarfism, Growth Disorders and Human Growth Hormone.
The authors tagged it with the keywords Bodily secretions, Child, Idiopathic short stature, Long-acting growth hormone and Serum growth hormone.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 4 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2022 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.